TWLO Twilio Inc gains 15% Apr 28, 2020

Twilio Inc. provides cloud communications platform that enables developers to build, scale, and operate communications within software applications through the cloud as a pay-as-you-go service in the United States and internationally. It offers programmable communications cloud software that enables developers to embed voice, messaging, video, and authentication capabilities into their applications through application programming interfaces. The company also provides use case products, such as a two-factor authentication solution. Twilio Inc. was founded in 2008 and is headquartered San Francisco, California.http://www.priceseries.com/trade/TWLO-Twilio-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2020040820200428.html

TGTX TG Therapeutics, Inc. gains 16% Apr 28, 2020

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.http://www.priceseries.com/trade/TGTX-TG-Therapeutics-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2020041620200428.html

SGEN Seattle Genetics, Inc. gains 32% Apr 29, 2020

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.http://www.priceseries.com/trade/SGEN-Seattle-Genetics-Inc-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2020032520200429.html

STNG Scorpio Tankers Inc. gains 29% Apr 29, 2020

Scorpio Tankers Inc., together with its subsidiaries, engages in the seaborne transportation of refined petroleum products worldwide. As of March 15, 2017, it owned 78 tankers comprising 22 LR2 tankers, 14 Handymax tankers, and 42 MR tankers with an average age of approximately 2.3 years; and 19 time chartered-in tankers, including 9 Handymax, 8 MR, 1 LR1, and 1 LR2 tankers. The company was founded in 2009 and is based in Monaco.http://www.priceseries.com/trade/STNG-Scorpio-Tankers-Inc-stock-gains-29-percent-a-Trade-Record-by-priceSeries-2020041420200429.html

RVP Retractable Technologies, Inc. gains 100% Apr 28, 2020

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare industry in the United States and internationally. Its principal products comprise VanishPoint 0.5mL insulin syringes; 1mL tuberculin, insulin, and allergy antigen syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL, and 10mL syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes; Patient Safe luer caps; and VanishPoint blood collection sets, as well as VanishPoint autodisable syringes. The company is also developing retractable needles and syringes, glass syringes, dental syringes, IV catheter introducers, and blood collection sets. It serves healthcare providers, such as acute care hospitals, alternate care facilities, doctors' offices, clinics, emergency centers, surgical centers, long-term care facilities, veterans administration facilities, military organizations, public health facilities, and prisons. The company distributes its products through a direct marketing network; and general line and specialty distributors, as well as through international distributors. Retractable Technologies, Inc. was founded in 1994 and is headquartered in Little Elm, Texas.http://www.priceseries.com/trade/RVP-Retractable-Technologies-Inc-stock-gains-100-percent-a-Trade-Record-by-priceSeries-2020040620200428.html

ROKU Roku, Inc. gains 30% Apr 28, 2020

http://www.priceseries.com/trade/ROKU-Roku-Inc-stock-gains-30-percent-a-Trade-Record-by-priceSeries-2020040920200428.html

QLYS Qualys, Inc. gains 21% Apr 28, 2020

Qualys, Inc. provides cloud-based security and compliance solutions in the United States and internationally. The company offers Qualys Cloud Suite, which includes Vulnerability Management, Continuous Monitoring, Cloud Agent, AssetView, ThreatPROTECT, Policy Compliance, PCI Compliance, Security Assessment Questionnaire, Web Application Scanning, and Web Application Firewall. Its integrated suite of security and compliance solutions delivered on its Qualys Cloud Platform enables customers to identify their IT assets, collect and analyze IT security data, discover and prioritize vulnerabilities, recommend remediation actions, and verify the implementation of such actions. The company also provides core services, including asset tagging and management, reporting and dashboards, questionnaires and collaboration, remediation and workflow, big data correlation and analytics engine, and alerts and notifications, which enable integrated workflows, management and real-time analysis, and reporting across IT security and compliance solutions. In addition, it offers cloud infrastructure services that include the data, data processing capabilities, software and hardware infrastructure, and infrastructure management capabilities. The company markets and sells its IT security and compliance solutions to customers directly through its sales teams, as well as indirectly through its network of channel partners, such as security consulting organizations, managed service providers, value added resellers, and consulting firms. It serves enterprises, government entities, and small and medium-sized businesses in various industries, including education, financial services, government, healthcare, insurance, manufacturing, media, retail, technology, and utilities. The company was founded in 1999 and is headquartered in Redwood City, California.http://www.priceseries.com/trade/QLYS-Qualys-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2020040220200428.html

PVG Pretium Resources, Inc. gains 25% Apr 28, 2020

Pretium Resources Inc. acquires, explores for, and develops precious metal resource properties in the Americas. It primarily explores for gold, silver, and copper deposits. The company owns 100% interests in the Brucejack project comprising 4 mining leases and 6 mineral claims covering an area of 3,304 hectares located in northwestern British Columbia; and the Snowfield project consisting of 1 mineral claim covering an area of 1,217 hectares located in northwestern British Columbia. Pretium Resources Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.http://www.priceseries.com/trade/PVG-Pretium-Resources-Inc-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2020040320200428.html

PBYI Puma Biotechnology Inc gains 18% Apr 29, 2020

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.http://www.priceseries.com/trade/PBYI-Puma-Biotechnology-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2020041620200429.html

NVAX Novavax, Inc. gains 76% Apr 29, 2020

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.http://www.priceseries.com/trade/NVAX-Novavax-Inc-stock-gains-76-percent-a-Trade-Record-by-priceSeries-2020032320200429.html

MTCH Match Group, Inc. gains 18% Apr 28, 2020

Match Group, Inc. provides dating products. It operates a portfolio of approximately 45 brands, including Match, OkCupid, Tinder, PlentyOfFish, Meetic, Twoo, OurTime, and FriendScout24. The company offers its dating products through its Websites and applications in 38 languages approximately in 190 countries. It also provides various test preparation, academic tutoring, and college counseling services. The company was incorporated in 2009 and is headquartered in Dallas, Texas. Match Group, Inc. is a subsidiary of IAC/InterActiveCorp.http://www.priceseries.com/trade/MTCH-Match-Group-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2020040320200428.html

MOBL MobileIron, Inc. gains 23% Apr 28, 2020

MobileIron, Inc. provides a purpose-built mobile IT platform that enables enterprises to secure and manage mobile applications, content, and devices while providing their employees with device choice, privacy, and a native user experience. Its MobileIron platform offers enterprise mobility management (EMM) solution that configures and delivers applications to smartphones, tablets, laptops, and desktops running operating systems, such as Android, iOS, macOS, and Windows 10; and secures data-at-rest and data-in-motion on modern endpoints and across the corporate network, as well as secures access to back-end corporate networks and cloud services. The company serves financial service, government, healthcare, legal, manufacturing, professional service, retail, technology, and telecommunication industries in the United States and internationally. MobileIron, Inc. was founded in 2007 and is headquartered in Mountain View, California.http://www.priceseries.com/trade/MOBL-MobileIron-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2020040620200428.html

KPTI Karyopharm Therapeutics Inc. gains 19% Apr 29, 2020

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.http://www.priceseries.com/trade/KPTI-Karyopharm-Therapeutics-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2020040820200429.html

JNPR Juniper Networks, Inc. gains 17% Apr 29, 2020

Juniper Networks, Inc. designs, develops, and sells network products and services worldwide. The company offers various routing products, such as ACX series universal access routers to deploy new high-bandwidth services; MX series Ethernet routers that functions as a universal edge platform; PTX series packet transport routers; cloud customer premises equipment; and NorthStar controllers. It also provides switching products, including EX series Ethernet switches to address the access, aggregation, and core layer switching requirements of micro branch, branch office, and campus and data center environments; QFX series of core, spine, and top-of-rack data center switches; and OCX1100, an open networking switch. In addition, the company offers security products comprising SRX series services gateways for the data centers; Branch SRX family that includes SRX300 Series and SRX1500, which provides integrated firewall capabilities; vSRX Virtual Firewall that delivers various features of physical firewalls; Sky Advanced Threat Prevention, a cloud-based service for static and dynamic analysis; and Spotlight Secure Threat Intelligence Platform, a threat intelligence platform that aggregates threat feeds from various sources. Further, it offers Junos OS, a network operating system; Junos Space, a network management platform for creating network management applications that include network director, services activation director, security director, edge services director, service now, and service insight; and Contrail networking and cloud platform solutions. Additionally, the company provides technical support and professional services, as well as education and training programs. It sells its products through direct sales, distributors, value-added resellers, and original equipment manufacturer partners to end-users in the service provider and enterprise markets. Juniper Networks, Inc. was founded in 1996 and is headquartered in Sunnyvale, California.http://www.priceseries.com/trade/JNPR-Juniper-Networks-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2020040220200429.html

JNJ Johnson & Johnson gains 17% Apr 29, 2020

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.http://www.priceseries.com/trade/JNJ-Johnson-&-Johnson-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2020040120200429.html

INCY Incyte Corp. gains 34% Apr 28, 2020

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.http://www.priceseries.com/trade/INCY-Incyte-Corp-stock-gains-34-percent-a-Trade-Record-by-priceSeries-2020033020200428.html

IDXX IDEXX Laboratories, Inc. gains 24% Apr 28, 2020

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.http://www.priceseries.com/trade/IDXX-IDEXX-Laboratories-Inc-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2020032520200428.html

IDRA Idera Pharmaceuticals, Inc. gains 16% Apr 28, 2020

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.http://www.priceseries.com/trade/IDRA-Idera-Pharmaceuticals-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2020041320200428.html

GRVY GRAVITY Co., Ltd. gains 21% Apr 28, 2020

Gravity Co., Ltd. develops and publishes online games in South Korea, Japan, the United States, Canada, Taiwan, Hong Kong, Macau, China, and internationally. It offers online games; mobile games and applications; and other games and game-related products and services, including character-based merchandise and animation. The company's massively multiplayer online role playing games include Ragnarok Online, Ragnarok Online II, Requiem, Dragonica, and R.O.S.E. Online. It also provides console games and a game for Internet protocol television; and licenses the merchandizing rights of character-related products based on its online games. In addition, the company markets dolls, stationery, food, and other character-based merchandise, as well as game manuals, monthly magazines, and other publications. Further, it provides Website development and operation services; and sells goods related to mobile phones, such as ornamental accessories and USB data cables. The company was founded in 2000 and is headquartered in Seoul, South Korea. Gravity Co., Ltd. operates as a subsidiary of GungHo Online Entertainment, Inc.http://www.priceseries.com/trade/GRVY-GRAVITY-Co-Ltd-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2020040820200428.html

GLPG Galapagos NV gains 18% Apr 28, 2020

Belgian biotech developing new treatments for inflammatory diseases.http://www.priceseries.com/trade/GLPG-Galapagos-NV-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2020032520200428.html

ARWR Arrowhead Research Corp. gains 28% Apr 29, 2020

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.http://www.priceseries.com/trade/ARWR-Arrowhead-Research-Corp-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2020040620200429.html

ALNY Alnylam Pharmaceuticals, Inc. gains 19% Apr 29, 2020

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.http://www.priceseries.com/trade/ALNY-Alnylam-Pharmaceuticals-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2020040820200429.html

AGTC Applied Genetic Technologies Corp. gains 15% Apr 29, 2020

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops genetic therapies to treat patients with inherited diseases. Its lead products consist of four ophthalmology development programs across three targets, including X linked retinoschisis (XLRS) that is in a Phase I/II clinical trials for the treatment of an inherited retinal disease; X-linked retinitis pigmentosa (XLRP), which is enrolling patients in a Phase I/II clinical trials; and achromatopsia (ACHM) that is enrolling patients in a Phase I/II clinical trials. Applied Genetic Technologies Corporation has collaboration agreements with Biogen MA, Inc.; 4D Molecular Therapeutics; and Synpromics Limited. The company was founded in 1999 and is headquartered in Alachua, Florida.http://www.priceseries.com/trade/AGTC-Applied-Genetic-Technologies-Corp-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2020040820200429.html

VSTM Verastem, Inc. gains 20% Apr 27, 2020

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company's product candidate FAK inhibitor, VS-6063, is in Phase 1 study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a Phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; a Phase II trial preceding surgery in mesothelioma; and a Phase 1/1b clinical trail in combination with avelumab in patients with ovarian cancer, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. It is also developing FAK inhibitor, VS-4718 that is in Phase 1, single-agent, dose escalation trial in patients with advanced cancers; and a Phase 1, dose-escalation clinical trial in combination with gemcitabine and nab-paclitaxel in patients with advanced solid tumors, as well as a Phase 1, dose-escalation clinical trial of PI3K/mTORC1/2 inhibitor, VS-5584, in patients with advanced non-hematologic malignancies or lymphoma. The company has license agreement with Whitehead Institute for Biomedical Research; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is based in Needham, Massachusetts.http://www.priceseries.com/trade/VSTM-Verastem-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2020040620200427.html

SELB Selecta Biosciences Inc gains 19% Apr 27, 2020

Selecta Biosciences Inc is a clinical-stage biopharmaceutical company using its proprietary synthetic vaccine particle technology to discover & develop targeted therapies designed to modulate the immune system to treat rare and serious diseases.http://www.priceseries.com/trade/SELB-Selecta-Biosciences-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2020040920200427.html

REGN Regeneron Pharmaceuticals, Inc. gains 16% Apr 27, 2020

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.http://www.priceseries.com/trade/REGN-Regeneron-Pharmaceuticals-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2020033020200427.html

EGOV NIC Inc. gains 34% Apr 27, 2020

NIC Inc., together with its subsidiaries, provides digital government services that enable governments to use technology to provide various services to businesses and citizens in the United States. The company's Outsourced Portals business enters into long-term contracts with state and local governments to design, build, and operate Internet-based, enterprise-wide portals on their behalf. These portals consist of Websites and applications that enable businesses and citizens to access government information online and complete transactions, such as applying for a permit, retrieving government records, or filing a government-mandated form or report. Its portal service offerings include motor vehicle driver history record retrieval; vehicle title, lien, and registration; motor vehicle inspections; temporary vehicle tags; driver's license renewal; hunting and fishing licenses; health professional license services; professional license renewal; business registrations and renewals; secretary of state business searches; Uniform Commercial Code (UCC) searches and filings; limited criminal history searches; court services; vital records; income and property tax payments; and payment processing products and services. The company's software & services business provides software development and payment processing services to state and local governments, as well as federal agencies. In addition, it develops and manages the pre-employment screening program for motor carriers using transaction-based business model. Further, the company offers consulting, application development, and portal management services to governments. NIC Inc. was founded in 1991 and is based in Olathe, Kansas.http://www.priceseries.com/trade/EGOV-NIC-Inc-stock-gains-34-percent-a-Trade-Record-by-priceSeries-2020031820200427.html

CSPI CSP Inc. gains 15% Apr 27, 2020

CSP Inc., together with its subsidiaries, develops and markets information technology (IT) integration solutions and cluster computer systems for commercial and defense customers in the Americas, Europe, and Asia. The company's High Performance Products segment offers computing systems for digital signal processing applications in the defense market; Ethernet adapters and solutions for various applications in the packet capture, financial transaction, broadcast video, and media markets, as well as ARC Series adapters for automated trading and network monitoring. Its Technology Solutions segment provides third-party computer hardware and software value added reseller services to various customers in Web and infrastructure hosting, education, telecommunications, healthcare services, distribution, financial and professional services, and manufacturing industries. This segment also offers professional IT consulting services, including implementation, integration, migration, configuration, installation, and project management services; unified storage platforms; virtualization solutions; enterprise security intrusion prevention, network access control, and unified threat management services; and IT security compliance services. Its professional IT consulting services also comprise unified communications, wireless and routing, and switching solutions; custom software applications and solutions development and support services; maintenance and technical support services; and managed IT services, such as monitoring, reporting, and management of alerts for the resolution and preventive general IT and IT security support tasks. This segment offers professional services for IT environments comprising advanced security, unified communications and collaboration, wireless and mobility, data center solutions, and network solutions. The company markets its products and services through direct sales force. CSP Inc. was founded in 1968 and is headquartered in Lowell, Massachusetts.http://www.priceseries.com/trade/CSPI-CSP-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2020040720200427.html

CLVS Clovis Oncology, Inc. gains 39% Apr 27, 2020

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.http://www.priceseries.com/trade/CLVS-Clovis-Oncology-Inc-stock-gains-39-percent-a-Trade-Record-by-priceSeries-2020040220200427.html

CEMI Chembio Diagnostics, Inc. gains 66% Apr 27, 2020

Chembio Diagnostics, Inc., together with its subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company's products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV 1/2 Assay Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a DPP HIV-Syphilis multiplex test for the detection of antibodies to HIV and syphilis; and a test for the detection of Hepatitis-C. Chembio Diagnostics, Inc. sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; and collaboration with an international diagnostics company to develop a POC diagnostic test for a specific type of cancer. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.http://www.priceseries.com/trade/CEMI-Chembio-Diagnostics-Inc-stock-gains-66-percent-a-Trade-Record-by-priceSeries-2020040720200427.html

APTO Aptose Biosciences, Inc. gains 18% Apr 27, 2020

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, a small molecule that induces the transcription of the Kruppel-like factor 4 Gene in in vitro studies and in in vivo pharmacodynamic studies of human xenograft tumors in mice. The company's APTO-253 clinical program has completed Phase-I clinical trials for the treatment of various solid tumors; and Phase-Ib clinical trials for relapsed/refractory hematologic malignancies. It also develops APTO-500 program that focuses on discovering and developing small molecule inhibitors of maternal embryonic leucine zipper kinase; and is in a pre-clinical stage for oncology. It has a license agreement with Genentech Inc. to develop and sub-license a specified polypeptide; and collaboration agreement with Eli Lilly and Company to investigate a proprietary series of the company's compounds for veterinary medicine. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.http://www.priceseries.com/trade/APTO-Aptose-Biosciences-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2020040620200427.html

TNET TriNet Group, Inc. gains 15% Apr 23, 2020

TriNet Group, Inc. provides human resources solutions for small and midsize businesses in the United States and Canada. The company offers multi-state payroll processing and tax administration; employee benefits programs, including health insurance and retirement plans; workers compensation insurance and claims management; local, state, and federal employment and benefit laws; and other services. It serves clients in various industries, including technology, life sciences, not-for-profit, professional services, financial services, property management, retail, manufacturing, and hospitality. The company markets its solutions through its sales representatives. TriNet Group, Inc. was founded in 1988 and is headquartered in San Leandro, California.http://www.priceseries.com/trade/TNET-TriNet-Group-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2020040620200423.html

SMMT Summit Therapeutics plc gains 55% Apr 23, 2020

Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.http://www.priceseries.com/trade/SMMT-Summit-Therapeutics-plc-stock-gains-55-percent-a-Trade-Record-by-priceSeries-2020040720200423.html

OSTK Overstock.com, Inc. gains 64% Apr 23, 2020

Overstock.com, Inc. operates as an online retailer in the United States. The company operates through two segments, Direct and Partner. It offers brand name, non-brand name, and closeout products, including furniture, home decor, bedding and bath, housewares, jewelry and watches, apparel and designer accessories, health and beauty products, electronics and computers, and sporting goods, among other products; and sells various books, magazines, CDs, DVDs, and video games. The company also provides handcraft, fresh produce and other food, and insurance products. Overstock.com, Inc. sells its products and services through its Internet Websites located at overstock.com, o.co, and o.biz, as well as through the United States based third party logistics providers to international customer. The company was formerly known as D2-Discounts Direct and changed its name to Overstock.com, Inc. in October 1999. Overstock.com, Inc. was founded in 1997 and is based in Midvale, Utah.http://www.priceseries.com/trade/OSTK-Overstockcom-Inc-stock-gains-64-percent-a-Trade-Record-by-priceSeries-2020040320200423.html

KTCC Key Tronic Corp. gains 19% Apr 23, 2020

Key Tronic Corporation, doing business as KeyTronicEMS Co., provides electronic manufacturing services (EMS) to original equipment manufacturers in the United States and internationally. The company offers integrated electronic and mechanical engineering, assembly, sourcing and procurement, logistics, and new product testing services. Its services include product design; surface mount technologies and pin through hole capability for printed circuit board assembly; tool making; precision plastic molding; sheet metal fabrication; liquid injection molding; complex assembly; automated tape winding; prototype design; and full product assembly services. The company also manufactures keyboards and other input devices. It markets its products and services primarily through field sales people and distributors. The company was founded in 1969 and is headquartered in Spokane Valley, Washington.http://www.priceseries.com/trade/KTCC-Key-Tronic-Corp-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2020040820200423.html

INFU InfuSystems Holdings, Inc. gains 62% Apr 23, 2020

InfuSystem Holdings Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, hospital outpatient, and chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole mounted and ambulatory infusion pumps; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, and others. It delivers local and field-based customer support, as well as operates pump service and repair centers. InfuSystem Holdings Inc. was founded in 2005 and is headquartered in Madison Heights, Michigan.http://www.priceseries.com/trade/INFU-InfuSystems-Holdings-Inc-stock-gains-62-percent-a-Trade-Record-by-priceSeries-2020032420200423.html

H Hyatt Hotels Corp. gains 15% Apr 23, 2020

Hyatt Hotels Corporation, a hospitality company, develops, owns, operates, manages, franchises, licenses, or provides services to full and select service hotels, resorts, and residential and other properties. It operates in four segments: Owned and Leased Hotels, Americas Management and Franchising, ASPAC Management and Franchising, and EAME/SW Asia Management and Franchising. The company operates its properties under the Hyatt, Park Hyatt, Miraval, Grand Hyatt, Hyatt Regency, Andaz, Hyatt Centric, The Unbound Collection by Hyatt, Hyatt Place, Hyatt House, Hyatt Ziva, Hyatt Zilara, Hyatt Residence Club, Hyatt Residences, Hyatt Gold Passport, and Hyatt Resorts brands and trademarks. As of December 31, 2016, its portfolio consisted of 698 properties in 56 countries. It primarily serves corporations; national, state, and regional associations; specialty market accounts, including social, government, military, educational, religious, and fraternal accounts; travel organizations; and a group of individual consumers. The company was formerly known as Global Hyatt Corporation and changed its name to Hyatt Hotels Corporation in June 2009. Hyatt Hotels Corporation was founded in 1957 and is headquartered in Chicago, Illinois.http://www.priceseries.com/trade/H-Hyatt-Hotels-Corp-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2020040620200423.html

GLMD Galmed Pharmaceuticals Ltd. gains 26% Apr 23, 2020

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of a once-daily, oral therapy for the treatment of liver diseases. It is developing Aramchol, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.http://www.priceseries.com/trade/GLMD-Galmed-Pharmaceuticals-Ltd-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2020040720200423.html

EQT EQT Corp. gains 73% Apr 23, 2020

EQT Corporation, together with its subsidiaries, operates as an integrated energy company in the United States. The company operates through three segments: EQT Production, EQT Gathering, and EQT Transmission. The EQT Production segment engages in the exploration for, development, and production of natural gas, natural gas liquids (NGLs), and crude oil primarily in the Appalachian Basin. As of December 31, 2016, this segment had 13.5 trillion cubic feet of proved natural gas, NGL, and crude oil reserves across approximately 3.6 million gross acres comprising approximately 790,000 gross acres in the Marcellus play. The EQT Gathering is involved in natural gas gathering activities. As of December 31, 2016, this segment operates approximately 300 miles of high pressure gathering lines with approximately 1.8 billion cubic feet of total firm gathering capacity and various interconnect points; and approximately 1,500 miles of FERC-regulated low pressure gathering lines. The EQT Transmission segment engages in natural gas transmission and storage activities. As of December 31, 2016, this segment operates approximately 950-mile FERC-regulated interstate pipeline that connects to six interstate pipelines and multiple distribution companies. EQT Corporation was founded in 1925 and is headquartered in Pittsburgh, Pennsylvania.http://www.priceseries.com/trade/EQT-EQT-Corp-stock-gains-73-percent-a-Trade-Record-by-priceSeries-2020040120200423.html

COG Cabot Oil & Gas Corp. gains 15% Apr 23, 2020

Cabot Oil & Gas Corporation, an independent oil and gas company, develops, exploits, explores for, produces, and markets natural gas, oil, and natural gas liquids in the United States. The company primarily focuses on the Marcellus Shale with approximately 179,000 net acres in the dry gas window of the play located in Susquehanna County, Pennsylvania; and the Eagle Ford Shale with approximately 84,000 net acres in the oil window of the play located in Atascosa, Frio, and La Salle Counties, Texas. It also transports, stores, gathers, and purchases natural gas for resale. The company sells its natural gas to industrial customers, local distribution companies, gas marketers, and power generation facilities through gathering systems and pipelines. As of December 31, 2016, it had proved reserves of approximately 8,576 billion cubic feet of natural gas equivalent. The company was founded in 1989 and is headquartered in Houston, Texas.http://www.priceseries.com/trade/COG-Cabot-Oil-&-Gas-Corp-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2020040320200423.html

CLBS Caladrius Biosciences, Inc. gains 19% Apr 23, 2020

Caladrius Biosciences, Inc. provides development and manufacturing services to the cell therapy industry in the United States. The company offers process development and clinical manufacturing services for therapeutic candidates in various stages of development. It is also developing CLBS03, a T regulatory cell clinical Phase II therapy targeting adolescents with type 1 diabetes. Caladrius Biosciences, Inc. has a strategic collaboration with Hitachi Chemical Co. America, Ltd. and Hitachi Chemical Co., Ltd. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.http://www.priceseries.com/trade/CLBS-Caladrius-Biosciences-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2020040320200423.html

BAK Braskem S.A. gains 17% Apr 23, 2020

Braskem S.A., together with its subsidiaries, produces and sells thermoplastic resins. Its Basic Petrochemicals segment offers olefins, such as ethylene, polymer and chemical grade propylene, butadiene, isoprene, and butene-1; BTX products comprising benzene, toluene, ortho-xylene, para-xylene, and mixed xylenes; fuels, including automotive gasoline and liquefied petroleum gas; intermediates, such as cumene; and other basic petrochemicals, which include ethyl tertiary butyl ether, solvent C9, and pyrolysis C9. This segment also supplies electric energy, steam, compressed air, and other products to second-generation producers. Its Polyolefins segment produces polyethylene, including LDPE, LLDPE, HDPE, ultra-high molecular weight polyethylene, and EVA; green polyethylene from renewable resources; and polypropylene. This segment's products are used in plastic films for food and industrial packaging; bottles, shopping bags, and other consumer goods containers; automotive parts; and household appliances. Its Vinyls segment produces polyvinyl chloride, caustic soda, chlorine, hydrogen, caustic soda flake, and sodium hypochlorite. The company's USA and Europe segment produces polypropylene in the United States and Germany. Its Chemical Distribution segment distributes solvents, including aliphatic, aromatic, synthetic, and ecologically-friendly solvents; engineering plastics; hydrocarbon solvents and isoparafins; and general purpose chemicals, such as process oils, chemical intermediates, blends, specialty chemicals, and pharmaceuticals. The company also imports and exports chemicals, petrochemicals, and fuels; produces, supplies, and sells utilities, such as water and industrial gases; and provides industrial services. The company was formerly known as Copene Petroquimica do Nordeste S.A. and changed its name to Braskem S.A. in 2002. Braskem S.A. was founded in 1972 and is headquartered in Sao Paulo, Brazil. Braskem S.A. is a subsidiary of Odebrecht S.A.http://www.priceseries.com/trade/BAK-Braskem-SA-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2020040820200423.html

SBRA Sabra Healthcare REIT, Inc. gains 22% Apr 20, 2020

Sabra Health Care REIT, Inc. operates as a real estate investment trust in the United States. The company, through its subsidiaries, owns and invests in real estate properties for the healthcare industry. Its property portfolio consists of 86 properties comprising 67 skilled nursing facilities; 10 combined skilled nursing, assisted living, and independent living facilities; 5 assisted living facilities; 2 mental health facilities; 1 independent living facility; and 1 continuing care retirement community. The company leases its properties to subsidiaries of Sun Healthcare Group, Inc. As of December 31, 2010, its properties had a total of 9,603 licensed beds or units across 19 states. The company is based in Irvine, California.http://www.priceseries.com/trade/SBRA-Sabra-Healthcare-REIT-Inc-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2020040620200420.html

OHI Omega Healthcare Investors, Inc. gains 16% Apr 20, 2020

Omega Healthcare Investors, Inc. is a real estate investment firm. The firm invests in the real estate markets of United States. It invests in healthcare facilities, primarily in long-term healthcare facilities in order to create its portfolio. Omega Healthcare Investors, Inc. was founded in 1992 and is based in Maryland, United States.http://www.priceseries.com/trade/OHI-Omega-Healthcare-Investors-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2020040620200420.html

NGL NGL ENERGY PARTNERS LP gains 20% Apr 20, 2020

NGL Energy Partners LP, through its subsidiaries, engages in the crude oil logistics, water solutions, liquids, retail propane, and refined products and renewables businesses in the United States. The Crude Oil Logistics segment purchases crude oil from producers and transports it for resale at pipeline injection points, storage terminals, barge loading facilities, rail facilities, refineries, and other trade hubs. The Water Solutions segment is involved in the treatment and disposal of wastewater generated from crude oil and natural gas production operations; disposal of solids, such as tank bottoms, drilling fluids, and performs truck washouts; and sale of recycled water and recovered hydrocarbons. The Liquids segment supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants in the United States and Canada. This segment also provides natural gas liquids terminaling and storage services through its 19 terminals in the United States; and leased storage and rail car transportation services through its fleet of leased rail cars. The Retail Propane segment sells propane, distillates, and equipment and supplies to end users consisting of residential, agricultural, commercial, and industrial customers, as well as re-sellers. The Refined Products and Renewables segment markets gasoline, diesel, ethanol, and biodiesel products; and purchase and delivers refined petroleum and renewable products. NGL Energy Holdings LLC serves as the general partner of the company. The company was founded in 1940 and is headquartered in Tulsa, Oklahoma.http://www.priceseries.com/trade/NGL-NGL-ENERGY-PARTNERS-LP-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2020040820200420.html

MOSY MoSys, Inc. gains 37% Apr 20, 2020

MoSys, Inc., a fabless semiconductor company, together with its subsidiaries, develops and sells integrated circuits (ICs) for the high-speed networking, communications, storage, and computing markets. It offers Bandwidth Engine, a memory-dominated IC that has been designed to be a companion IC to packet processors; and LineSpeed IC product line, a non-memory, high-speed SerDes I/O device with clock data recovery, gearbox, and retimer functionality, which converts lanes of data received on line cards or by optical modules into various configurations and/or ensure signal integrity. The company serves networking and communications systems original equipment manufacturers. MoSys, Inc.markets and sells its products through sales and marketing personnel, sales representatives, and distributors in North America, Taiwan, Japan, China, rest of Asia, and Europe. The company was founded in 1991 and is headquartered in Santa Clara, California.http://www.priceseries.com/trade/MOSY-MoSys-Inc-stock-gains-37-percent-a-Trade-Record-by-priceSeries-2020040820200420.html

MGP MGM Growth Properties LLC gains 26% Apr 20, 2020

MGM Growth Properties LLC engages in owning, acquiring, and leasing casino resort properties in the United States. It resorts provide casino gaming, hotel, convention, dining, entertainment, retail and mixed-use facilities, and other resort amenities. As of December 31, 2015, the company's properties include a total of 24,466 hotel rooms. MGM Growth Properties LLC was founded in 2015 and is based in Las Vegas, Nevada. MGM Growth Properties LLC operates as a subsidiary of MGM Resorts International.http://www.priceseries.com/trade/MGP-MGM-Growth-Properties-LLC-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2020032420200420.html

MACK Merrimack Pharmaceuticals, Inc. gains 54% Apr 20, 2020

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. It offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The company's therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trial for treating patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trial for the treatment of glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trial for treating metastatic breast cancer. Its therapeutic oncology candidates also include MM-302 for treating patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, the company's therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; MM-151 that has completed a Phase I clinical trial for treating solid tumors; and MM-310 for treating solid tumors. Further, it is developing preclinical product candidates for solid tumor indications. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.http://www.priceseries.com/trade/MACK-Merrimack-Pharmaceuticals-Inc-stock-gains-54-percent-a-Trade-Record-by-priceSeries-2020033020200420.html

LIQT LiqTech Intl., Inc. gains 19% Apr 20, 2020

LiqTech International, Inc., a clean technology company, provides technologies for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company manufactures and sells ceramic silicon carbide membranes for liquid filtration under the LiqTech, Cometas, and Provital brand names, which are used for the filtration of produced water, pre-filtration of reverse osmosis drinking water, industrial applications, producing clean drinking water, and waste water treatment. It also offers diesel particulate filters for exhaust emission control solutions to the verified retrofit and the original equipment manufacturer market; and kiln furniture for the refractory industry to support ceramics that create additional space to maximize the number of items for each firing. LiqTech International, Inc. sells its products primarily to industrial customers in the United States, Canada, Europe, Asia, and South America. The company was formerly known as Blue Moose Media, Inc. and changed its name to LiqTech International, Inc. in October 2011. LiqTech International, Inc. was founded in 2004 and is headquartered in Ballerup, Denmark.http://www.priceseries.com/trade/LIQT-LiqTech-Intl-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2020040220200420.html

KODK Eastman Kodak Company gains 17% Apr 20, 2020

Eastman Kodak Company provides hardware, software, consumables, and services to customers in various markets worldwide. The company operates through seven segments: Print Systems; Micro 3D Printing and Packaging; Software and Solutions; Consumer and Film; Enterprise Inkjet Systems; Intellectual Property Solutions; and Eastman Business Park. It offers digital offset plate and computer-to-plate imaging solutions, and electro photographic printing solutions to a range of commercial industries, including commercial print, direct mail, book publishing, newspapers and magazines, and packaging. The company also provides flexographic printing equipment and plates, and related consumables and services, as well as printed functional materials and components; suite of software solutions for print production workflow, as well as print and managed media services; motion picture and industrial films, chemicals, and inks; and publishing, transactional, commercial print, and direct mail systems, as well as licenses Kodak brands to third parties, and consumer products. In addition, it offers intellectual property solutions; and leases technology center and industrial complex. The company sells its products and services through third party resellers and distributors, as well as directly and indirectly to enterprise accounts and customers. Eastman Kodak Company was founded in 1880 and is headquartered in Rochester, New York.http://www.priceseries.com/trade/KODK-Eastman-Kodak-Company-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2020040620200420.html